An interventional study of Supervised Home-Based Exercise and Unsupervised Home-Based Exercise in Breast Cancer, Colorectal Cancer and Prostate Cancer, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 29th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2022, is one of 52 with no phase, reaches primary completion later than 19 of the 42 other live ones, and was the 123rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18–49 · Women only
Dana-Farber Cancer Institute · Sites in United States
Ages 80+ · Women only · Healthy volunteers
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 60 · Phase 3 2
First in 1998; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 135 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 50 across the 132 interventional studies, 112 across the 10 observational. Of the 95 that completed or were terminated, 45 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
12 of the studies in Breast Neoplasms by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04434040Dana-Farber Cancer InstituteAtezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | 2026-12-30 |
| NCT05327452Dana-Farber Cancer InstituteTesting Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | 2026-12-31 |
| NCT07482384Dana-Farber Cancer InstituteSupporting Health Including Endocrine Treatment for Long Duration | 2027-01 |
| NCT04379414Dana-Farber Cancer InstituteYES Study - Newly Diagnosed/Metastatic Intervention | 2027-03-01 |
| NCT04468061Dana-Farber Cancer InstituteSacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | 2027-04-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients.
The names of the study interventions involved in this study are:
This is a randomized control trial of Black and Hispanic patients who have been newly diagnosed with breast, colorectal, or prostate cancer and are being prescribed chemotherapy to determine the effects of home-based exercise on levels of physical activity. It will also evaluate the impact of home-based exercise on cardiovascular (heart health) risk factors.
The research study procedures include: screening for eligibility and study treatment including evaluations of body composition, blood tests, fitness and strength assessments, and surveys at study entry and follow-up visits.
Participants in this study will be randomly assigned to one of three groups: 1) Supervised aerobic and resistance exercise (SUP), 2) Unsupervised aerobic and resistance exercise (UNSUP), or 3) Attention control (AC).
Participation is expected to last for 8 months.
It is expected that about 135 people will take part in this research study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomly assigned to receive 3x weekly at home, virtually supervised aerobic and resistance exercise sessions with a certified exercise trainer for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.
Behavioral: Supervised Home-Based Exercise
Participants will be randomly assigned to receive 3x weekly at home, unsupervised aerobic and resistance exercise sessions with a 1x weekly telehealth call with a certified exercise trainer for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.
Behavioral: Unsupervised Home-Based Exercise
Participants will be randomly assigned to receive 3x weekly at home stretching exercise for 16 weeks. Participants will also have a baseline test, mid intervention cardiovascular and strength tests and one postintervention and one follow up visit.
Behavioral: Attention Control
Online supervised aerobic and resistance exercise
Unsupervised aerobic and resistance exercise (UNSUP)
Stretching Program
Change in Physical Activity Participation
Changes from baseline in physical activity participation measured by Godin Leisure-Time Exercise Questionnaire.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Biomarkers for Cardiovascular and Metabolic Health - insulin
Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Insulin will be measured.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Blood Pressure
Blood pressure will be assessed using an automated blood pressure cuff to measure both systolic and diastolic blood pressure.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Body Composition
Body composition (lean mass and fat mass) will be assessed via bioelectrical impedance using a validated scale.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Cardiopulmonary Fitness
Cardiopulmonary fitness will be measured by a submaximal graded exercise cycling test.
Time frame: Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up
Physical Fitness
Physical Fitness will be measured by the short physical performance battery (SPPB).
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Cardiorespiratory Fitness
Cardiorespiratory fitness will be assessed by the 6-minute walk test.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Muscular Strength
Muscular strength will be assessed with a 10 repetition maximum test.
Time frame: Evaluated at week 1 for baseline, week 9 for mid-point, week 16 for post-intervention assessment, and week 32 for follow-up
Patient Reported Outcomes - Quality of Life
Quality of life will be assessed by EORTC QLQ C-30.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Patient Reported Outcomes - Health-related domains
Health-related domains of patient reported outcomes will be assessed by PROMIS-29 Profile v2.1.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Patient Reported Outcomes - Sleep
Quality of life will be assessed by the Pittsburg Sleep Quality Index (PSQI).
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Patient Reported Outcomes - Symptoms
Symptomatic toxicities will be assessed by PRO-CTCAE.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Dietary Assessment
Dietary recall will be used to assess recent dietary patterns for two weekdays and one weekend day using NutriBase 11.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Acceptability of Intervention Questionnaire Ratings
Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable.
Time frame: Evaluated at months 2 and 4
Feasibility of Intervention Questionnaire Ratings
Intervention acceptability and feasibility will be assessed via Acceptability of Intervention and Feasibility of Intervention questionnaires. Items are measured on a 5-point Likert scale (completely disagree to completely agree). Score is calculated mean. An average rating of 4 or higher will be considered feasible/acceptable.
Time frame: Evaluated at months 2 and 4
Augmentation Index
Augmentation index (a marker for arterial stiffness) will also be assessed using Mobil-O-Graph device.
Time frame: Time Frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Biomarkers for Cardiovascular and Metabolic Health - glucose
Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. Glucose will be measured.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up
Biomarkers for Cardiovascular and Metabolic Health - HbA1c
Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. HbA1c will be measured.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.
Biomarkers for Cardiovascular and Metabolic Health - c-peptide
Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-peptide (biomarkers of glycemic control and insulin resistance) will be measured.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.
Biomarkers for Cardiovascular and Metabolic Health - c-reactive protein
Fasting blood will be drawn from the antecubital vein by a trained phlebotomist. C-reactive protein (CRP; biomarker of system inflammation) will be measured.
Time frame: Evaluated at week 1 for baseline, week 16 for post-intervention assessment, and week 32 for follow-up.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 50 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →